IgA Nephropathy Market Analysis, Epidemiology, and Forecast Through 2034

DelveInsight's comprehensive "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" analysis delivers extensive understanding of IgA Nephropathy, historical and projected epidemiology alongside the IgA Nephropathy market trends across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For comprehensive details about the IgA Nephropathy market perspective, drug adoption, treatment landscape and epidemiology patterns, Click here; IgA Nephropathy Market Forecast

Major Highlights from the IgA Nephropathy Market Analysis:

The IgA Nephropathy market dimension was estimated at approximately USD 730 million in 2024 and is projected to expand with substantial CAGR throughout the analysis timeframe (2020-2034).

During November 2025, The FDA awarded approval to sibeprenlimab-szsi (Voyxact; Otsuka) for lowering proteinuria in adults diagnosed with immunoglobulin A nephropathy (IgAN), supported by interim outcomes from the phase 3 VISIONARY trial (NCT05248646). The therapy is administered as a subcutaneous self-injection using a prefilled syringe every four weeks at home, with a recommended dose of 400 mg per administration.

During November 2025, Voyxact (sibeprenlimab-szsi) represents a newly FDA-approved treatment engineered to reduce proteinuria in adults diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. IgAN is a chronic kidney disorder caused by the accumulation of IgA antibodies in the kidneys, triggering inflammation and tissue damage. This process produces elevated protein levels in the urine and a progressive loss of kidney function. Without appropriate treatment, IgAN can ultimately progress to kidney failure.

During September 2025, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) disclosed notable progress across its programs for immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD), and autosomal dominant polycystic kidney disease (ADPKD). These developments mark significant strides toward the company's mission of delivering first-in-class or best-in-class therapies that address the root causes of these serious kidney conditions.

During September 2025, CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) have expressed support for the newly published KDIGO 2025 clinical practice guideline for managing IgA Nephropathy (IgAN) and Immunoglobulin A vasculitis. The updated guidelines outline diagnostic criteria, treatment objectives, and management strategies, aiming to advance care for patients diagnosed with IgAN and provide guidance for clinicians treating them.

During May 2025, Otsuka Pharmaceuticals disclosed that the FDA has accepted the Biologics License Application (BLA) for sibeprenlimab, an APRIL (a proliferation-inducing ligand) inhibitor under development for managing immunoglobulin A nephropathy (IgAN). This follows the FDA's 2024 Breakthrough Therapy Designation granted to sibeprenlimab for the same condition. The BLA submission is backed by data from the Phase III VISIONARY trial. According to GlobalData, the priority review underscores sibeprenlimab's potential advantages over current therapies and reinforces its promise as a treatment for the complex nature of IgAN. If approved, it would become the first disease-modifying option addressing both clinical and practical aspects of managing IgAN.

During March 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced topline findings from Part 2 of its Phase 1/2 clinical trial evaluating ARO-C3, an investigational RNA interference (RNAi) therapy aimed at lowering liver production of complement component 3 (C3) to potentially treat multiple complement-mediated disorders.

During November 2024, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical Co., Ltd. disclosed plans to submit a Biologics License Application (BLA) in the U.S. for sibeprenlimab, an investigational therapy for adult patients diagnosed with immunoglobulin A nephropathy (IgA nephropathy), in the first half of 2025. This decision follows a recent meeting with the U.S. FDA to review the positive interim findings from the Phase 3 VISIONARY trial (NCT05248646).

During January 2024, Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company in advanced stages of clinical development focused on innovative treatments for individuals with severe immunologic conditions, announced the addition of two seasoned industry professionals to spearhead the advancement of the company's drug initiatives. This includes their late-stage candidate, atacicept, presently undergoing a Phase 3 clinical trial for IgA nephropathy (IgAN). Effective immediately, Robert M. Brenner, M.D., assumes the role of Chief Medical Officer, succeeding Dr. Celia Lin, M.D., while William D. Turner takes on the position of Chief Development Officer.

During 2024, the market dimension for IgA Nephropathy (IgAN) in the US was approximately USD 455 million and is anticipated to expand with the introduction of emerging therapies.

The total market dimension for the EU4 and the UK was estimated at approximately USD 150 million in 2024, representing nearly 21% of the overall market revenue for the 7MM, with expansion expected by 2034.

During 2024, Germany led the IgAN market among the EU4 and the UK with approximately USD 45 million in revenue, followed by France at approximately USD 35 million and Italy at nearly USD 30 million.

During 2024, Japan's IgAN market dimension was estimated at approximately USD 125 million, with expectations of growth throughout the forecast period from 2025 to 2034.

DelveInsight estimates that approximately 415,000 prevalent cases of IgA Nephropathy (IgAN) were reported across the 7MM in 2024. These diagnosed cases are anticipated to expand at a CAGR of 0.6% by 2034.

During 2024, the United States reported approximately 133,000 diagnosed prevalent cases of IgA Nephropathy (IgAN), with numbers projected to rise by 2034.

During 2024, Germany demonstrated the highest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) among the EU4 and the UK, with approximately 30,000 cases, while Spain recorded the lowest, with approximately 5,000 cases.

During 2024, Japan reported the highest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) among the 7MM, with nearly 175,000 cases, and this number is projected to increase by 2034.

During 2024, France reported approximately 16,000 diagnosed prevalent cases of IgA Nephropathy (IgAN) in males and 8,000 in females, with both numbers anticipated to increase by 2034.

Leading IgA Nephropathy pharmaceutical organizations: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, among others

Primary IgA Nephropathy therapeutic agents: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, among others

The IgA Nephropathy epidemiology assessment based on gender revealed that IgAN is more prominent in males in comparison to females. Prevalence of IgAN manifests in men approximately two times more than females worldwide.

The IgA Nephropathy marketplace is projected to experience substantial growth driven by rising disease prevalence and enhanced awareness throughout the projection timeframe. Additionally, the introduction of numerous multi-phase IgA Nephropathy pipeline candidates will considerably transform the market landscape dynamics.

IgA Nephropathy Disease Background

IgA nephropathy, also designated as Berger's disease, represents a kidney disorder marked by the buildup of the antibody immunoglobulin A (IgA) in the kidneys. This buildup can result in inflammation and damage to the tiny filters in the kidneys called glomeruli. IgA nephropathy is one of the most common forms of glomerulonephritis, which is inflammation of the glomeruli.

Access a complimentary sample for the IgA Nephropathy Market Forecast, Size & Share Analysis:

https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

IgA Nephropathy Epidemiology Analysis

The epidemiology segment delivers insights into historical, current, and projected epidemiology patterns across the seven major countries (7MM) from 2020 through 2034. It facilitates recognition of causes underlying current and forecasted patterns by examining multiple studies and perspectives of key opinion leaders. The epidemiology segment additionally provides comprehensive analysis of the diagnosed patient population and emerging trends.

IgA Nephropathy Epidemiology Classification:

The IgA Nephropathy market analysis presents epidemiological evaluation for the study period 2020–2034 across the 7MM categorized into:

Total Prevalence of IgA Nephropathy

Prevalent Cases of IgA Nephropathy by severity classification

Gender-specific Prevalence of IgA Nephropathy

Diagnosed Cases of Episodic and Chronic IgA Nephropathy

Access the analysis to comprehend which elements are influencing IgA Nephropathy epidemiology patterns @ IgA Nephropathy Epidemiology Forecast

IgA Nephropathy Drug Adoption and Pipeline Activities

The drug adoption segment concentrates on the uptake velocity of potential therapeutic agents recently introduced in the IgA Nephropathy marketplace or anticipated to launch during the analysis period. The evaluation encompasses IgA Nephropathy market adoption by drugs, patient adoption by treatment modalities, and revenue of individual drugs.

Furthermore, the therapeutics evaluation segment facilitates understanding of drugs demonstrating the most accelerated adoption and underlying reasons for maximal utilization. Additionally, it compares therapeutic agents based on market penetration.

The analysis also encompasses the IgA Nephropathy Pipeline Development Activities. It delivers valuable insights regarding various therapeutic candidates across multiple phases and primary organizations engaged in developing targeted therapies. It additionally analyzes recent advancements including collaborations, acquisitions, mergers, licensing patent information, and other intelligence for emerging therapeutic agents.

IgA Nephropathy Therapeutic Agents and Leading Organizations

VANRAFIA (atrasentan): Novartis

FILSPARI (sparsentan): Travere Therapeutics

TARPEYO/KINPEYGO (budesonide): Asahi Kasei (Calliditas Therapeutics)

Povetacicept (ALPN-303): Vertex Pharmaceuticals

Atacicept: Vera Therapeutics

Zigakibart (FUB523): Novartis

Sibeprenlimab: Visterra

Atrasentan: Chinook Therapeutics

LNP023: Novartis Pharmaceuticals

Research programme: IgA proteases Selecta Biosciences

AP 305: Shanghai Alebund Pharmaceuticals

ADR-001: Rohto Pharmaceutical

MY 008: Wuhan Createrna Science and Technology

SHR-2010: Guangdong Hengrui Pharmaceutical

IONIS FB: LRx Ionis Pharmaceuticals

HR19042: Jiangsu HengRui Medicine Co., Ltd.

Sparsentan: Travere Therapeutics

HR19042: Jiangsu HengRui Medicine Co., Ltd.

Explore additional information about therapeutic agents positioned to capture significant IgA Nephropathy market penetration @ IgA Nephropathy Treatment Landscape

IgA Nephropathy Market Growth Factors

Expansion in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness represent some of the significant factors fueling the IgA Nephropathy marketplace.

IgA Nephropathy Market Obstacles

Nevertheless, absence of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases, and other factors are creating challenges in the IgA Nephropathy marketplace growth.

Coverage of the IgA Nephropathy Market Analysis

Analysis Period: 2020–2034

Geographic Coverage: 7MM 

Leading IgA Nephropathy Pharmaceutical Organizations: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, among others.

Primary IgA Nephropathy Therapeutic Agents: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, among others

IgA Nephropathy Therapeutic Evaluation: IgA Nephropathy current commercialized and IgA Nephropathy investigational therapies

IgA Nephropathy Market Dynamics: IgA Nephropathy market growth factors and IgA Nephropathy market obstacles

Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry methodologies

IgA Nephropathy Unmet Requirements, KOL perspectives, Analyst perspectives, IgA Nephropathy Market Access and Reimbursement

For additional information about IgA Nephropathy organizations operating in the treatment marketplace, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

Report Structure

1. IgA Nephropathy Market Analysis Introduction

2. Executive Summary for IgA Nephropathy

3. SWOT evaluation of IgA Nephropathy

4. IgA Nephropathy Patient Distribution (%) Overview at a Glance

5. IgA Nephropathy Market Overview at a Glance

6. IgA Nephropathy Disease Background and Overview

7. IgA Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of IgA Nephropathy

9. IgA Nephropathy Current Treatment and Medical Practices

10. IgA Nephropathy Unmet Requirements

11. IgA Nephropathy Emerging Therapeutic Agents

12. IgA Nephropathy Market Perspective

13. Country-Wise IgA Nephropathy Market Evaluation (2020–2034)

14. IgA Nephropathy Market Access and Reimbursement of Therapeutic Agents

15. IgA Nephropathy Market Growth Factors

16. IgA Nephropathy Market Obstacles

17. IgA Nephropathy Appendix

18. IgA Nephropathy Analysis Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a prominent Healthcare Business Consultant and Market Research organization focused exclusively on life sciences. It supports pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance.

It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and overcome obstacles with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com